Reuters logo
CORRECTED-Amgen parathyroid drug succeeds in late-stage trial (Aug 18)
August 19, 2014 / 12:56 PM / 3 years ago

CORRECTED-Amgen parathyroid drug succeeds in late-stage trial (Aug 18)

(Corrects headline and paragraph 1 in Aug. 18 story to replace “thyroid” with “parathyroid”))

Aug 18 (Reuters) - Drugmaker Amgen Inc said its experimental drug to reduce parathyroid levels in patients with chronic kidney disease met the main goal in a late-stage trial.

The drug, AMG 416, treats hyperparathyroidism, or excessive secretion of parathyroid hormone, in kidney disease patients.

The results follow the recent announcement of positive data from a placebo-controlled late-stage study of AMG 416, which was similar in design and size. (Reporting By Amrutha Penumudi in Bangalore)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below